Published in Crit Care Med on April 01, 2016
Prospective Testing and Redesign of a Temporal Biomarker Based Risk Model for Patients With Septic Shock: Implications for Septic Shock Biology. EBioMedicine (2015) 0.77
Matrix Metalloproteinase-8 Augments Bacterial Clearance in a Juvenile Sepsis Model. Mol Med (2016) 0.75
Is Matrix Metalloproteinase-8 Activity in the Mucosal Barrier a Requirement for Leakage of Cecal Material in Peritonitis? Crit Care Med (2016) 0.75
Role of matrix metalloproteinase-8 as a mediator of injury in intestinal ischemia and reperfusion. FASEB J (2016) 0.75
Chemical chaperone TUDCA prevents apoptosis and improves survival during polymicrobial sepsis in mice. Sci Rep (2016) 0.75
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med (2005) 13.40
Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med (2012) 4.45
Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev (1999) 2.96
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med (2007) 2.58
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol (2007) 2.36
A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med (2012) 2.11
Association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med (2014) 2.05
LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS One (2007) 2.01
The pediatric sepsis biomarker risk model. Crit Care (2012) 1.99
Validating the genomic signature of pediatric septic shock. Physiol Genomics (2008) 1.96
Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov (2014) 1.85
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J (2007) 1.74
Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol (2004) 1.57
Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock (2007) 1.50
To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta (2009) 1.48
Genome-wide expression profiling in pediatric septic shock. Pediatr Res (2013) 1.39
Matrix metalloproteinase-8 inactivates macrophage inflammatory protein-1 alpha to reduce acute lung inflammation and injury in mice. J Immunol (2009) 1.30
Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol (2005) 1.29
Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. Crit Care Med (2000) 1.19
Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am J Pathol (2010) 1.19
Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-α activation. J Immunol (2014) 0.99
Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J Biol Chem (2008) 0.98
Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J Immunol (2013) 0.96
MMP-8 genotypes influence the inflammatory response in human endotoxemia. Inflammation (2014) 0.86
MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia. PLoS One (2012) 0.83
Matrix metalloproteinase-8 as a potential drug target for the therapy of sepsis. Crit Care Med (2012) 0.82
A multibiomarker-based outcome risk stratification model for adult septic shock*. Crit Care Med (2014) 2.94
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med (2007) 2.58
Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med (2008) 2.32
Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis. Crit Care Med (2003) 2.25
Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care Med (2013) 2.14
Dexamethasone decreases neurological sequelae and caspase activity. Intensive Care Med (2004) 2.12
A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med (2012) 2.11
Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med (2015) 2.09
Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med (2011) 2.08
The pediatric sepsis biomarker risk model. Crit Care (2012) 1.99
Validating the genomic signature of pediatric septic shock. Physiol Genomics (2008) 1.96
Admission angiopoietin levels in children with septic shock. Shock (2007) 1.82
Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med (2005) 1.79
Zinc homeostasis in pediatric critical illness. Pediatr Crit Care Med (2009) 1.77
Post-ICU admission fluid balance and pediatric septic shock outcomes: a risk-stratified analysis. Crit Care Med (2014) 1.72
A survey of stated physician practices and beliefs on the use of steroids in pediatric fluid and/or vasoactive infusion-dependent shock. Pediatr Crit Care Med (2013) 1.63
The host response to sepsis and developmental impact. Pediatrics (2010) 1.62
Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med (2010) 1.60
Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock (2002) 1.59
Endothelial progenitor cells and a stromal cell-derived factor-1α analogue synergistically improve survival in sepsis. Am J Respir Crit Care Med (2014) 1.59
The influence of developmental age on the early transcriptomic response of children with septic shock. Mol Med (2011) 1.57
Admission chemokine (C-C motif) ligand 4 levels predict survival in pediatric septic shock. Pediatr Crit Care Med (2010) 1.57
Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med (2014) 1.56
Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. J Immunol (2006) 1.55
Lung injury after hemorrhage is age dependent: role of peroxisome proliferator-activated receptor gamma. Crit Care Med (2009) 1.55
Calpain inhibition decreases endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest. Crit Care Med (2005) 1.50
Erythropoietin: a role in intensive care beyond erythropoiesis? Crit Care Med (2006) 1.50
A Multibiomarker-Based Model for Estimating the Risk of Septic Acute Kidney Injury. Crit Care Med (2015) 1.49
Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock (2008) 1.48
Caspases inhibition decreases neurological sequelae in meningitis. Crit Care Med (2008) 1.46
Genetic association research: understanding its challenges and limitations. Pediatr Crit Care Med (2010) 1.46
The PICU perspective on monitoring hemodynamics and oxygen transport. Pediatr Crit Care Med (2011) 1.46
Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J Cell Biol (2006) 1.41
Glucocorticoid Receptor Expression in Peripheral WBCs of Critically Ill Children. Pediatr Crit Care Med (2015) 1.41
Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4- and NF-kappaB-dependent mechanism. J Immunol (2007) 1.40
The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity (2011) 1.39
Beta-arrestin 2 negatively regulates sepsis-induced inflammation. Immunology (2010) 1.33
Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med (2003) 1.33
Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care (2012) 1.31
Heat shock response and acute lung injury. Free Radic Biol Med (2006) 1.29
Hepatocyte NF-kappaB activation is hepatoprotective during ischemia-reperfusion injury and is augmented by ischemic hypothermia. Am J Physiol Gastrointest Liver Physiol (2006) 1.28
Contribution of MKP-1 regulation of p38 to endotoxin tolerance. Shock (2005) 1.28
Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther (2011) 1.27
Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol (2002) 1.23
Pediatric septic shock treatment: new clues from genomic profiling. Pharmacogenomics (2007) 1.22
Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics (2010) 1.22
Corticosteroids are associated with repression of adaptive immunity gene programs in pediatric septic shock. Am J Respir Crit Care Med (2014) 1.20
Pediatric sepsis: challenges and adjunctive therapies. Crit Care Clin (2013) 1.19
Role of biomarkers in sepsis care. Shock (2013) 1.19
Pathophysiology and treatment of septic shock in neonates. Clin Perinatol (2010) 1.17
Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray. Crit Care (2011) 1.16
Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage. FASEB J (2002) 1.16
Incorporation of biomarkers with the renal angina index for prediction of severe AKI in critically ill children. Clin J Am Soc Nephrol (2014) 1.15
Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov (2009) 1.14
Overexpression of Hsp20 prevents endotoxin-induced myocardial dysfunction and apoptosis via inhibition of NF-kappaB activation. J Mol Cell Cardiol (2009) 1.14
Lipopolysaccharide- and gram-positive bacteria-induced cellular inflammatory responses: role of heterotrimeric Galpha(i) proteins. Am J Physiol Cell Physiol (2005) 1.13
Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med (2004) 1.12
Plasma angiopoietin-2 levels increase in children following cardiopulmonary bypass. Intensive Care Med (2008) 1.10
Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology (2008) 1.09
Activation of hepatocytes by extracellular heat shock protein 72. Am J Physiol Cell Physiol (2008) 1.07
The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol (2002) 1.07
Theaflavin, a black tea extract, is a novel anti-inflammatory compound. Crit Care Med (2004) 1.06
Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J Immunol (2003) 1.06
Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med (2008) 1.06
Age-dependent responses to hepatic ischemia/reperfusion injury. Shock (2005) 1.06
Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respir Res (2009) 1.05
Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol (2007) 1.04
Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med (2007) 1.04
Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr (2004) 1.04
beta-Arrestin 2: a Negative Regulator of Inflammatory Responses in Polymorphonuclear Leukocytes. Int J Clin Exp Med (2008) 1.01
A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation (2002) 1.01
Role of heat shock protein 70 in hepatic ischemia-reperfusion injury in mice. Am J Physiol Gastrointest Liver Physiol (2006) 1.01
Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol (2014) 1.01
Identifying critically ill patients who may benefit from adjunctive corticosteroids: not as easy as we thought. Pediatr Crit Care Med (2014) 1.00
Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways. Mol Med (2008) 1.00
Reduced peroxisome proliferator-activated receptor α expression is associated with decreased survival and increased tissue bacterial load in sepsis. Shock (2012) 0.99
Glutamine's protection against cellular injury is dependent on heat shock factor-1. Am J Physiol Cell Physiol (2006) 0.98
The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology. Expert Rev Anti Infect Ther (2014) 0.98
Interleukin 27 as a sepsis diagnostic biomarker in critically ill adults. Shock (2013) 0.98
Decompressive abdominal laparotomy for abdominal compartment syndrome in an unengrafted bone marrow recipient with septic shock. Crit Care Res Pract (2010) 0.96